91高清自产国产拍,无码免费A级毛片大全,日本欧美国产中文字幕,99re热视频这里只有精品视频首页

首页

400-620-6333

提交您使用阿拉丁产品的研究文章，就得100元奖励！立即访问我们的提交页面.

跳到内容

语言

切换导航

我的购物车

搜索

菜单

账号

设置

语言

Ipilimumab (anti-CTLA-4)

规格或纯度: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

种属反应性: Cynomolgus,Human,Mouse?
亚型: Human IgG1

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
I411993-1mg	1mg	期货
I411993-5mg	5mg	期货
I411993-10mg	10mg	期货

查看相关系列

cytotoxic T-lymphocyte-associated protein 4 (CD152) Antibody

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本信息

产品名称	Ipilimumab (anti-CTLA-4)
规格或纯度	Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
特异性	CTLA-4/CD152
应用	ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
反应种属	Cynomolgus,Human,Mouse?
偶联标记	Unconjugated

产品属性

抗体类型	Primary antibody
Format	Whole IgG
亚型	Human IgG1
轻链亚型	Kappa
SDS-PAGE	26.9 kDa (Light Chain) & 52.7 kDa (Heavy Chain), under reducing conditions; 176.3 kDa, under non-reducing conditions.
纯化方法	Protein A purified
来源	CHO supernatant
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	Lot by Lot
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	Store at -80℃ for 18 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS编号和信息	477202-00-9

数据库链接

IMGT/mAb-DB	180
PubChem SID	178103470
Wikipedia	Ipilimumab

靶标

Target ID

2743

名称

cytotoxic T-lymphocyte-associated protein 4 (CD152)

缩写名

CTLA-4

家族

Other immune checkpoint proteins

别名

KCa2.1

基因和蛋白信息

Species	Transmembrane Domains	Amino Acids	Chromosomal Location	Gene Symbol	Gene Name
Human	1	223	2q33.2	CTLA4	cytotoxic T-lymphocyte associated protein 4
Mouse	1	223	1 30.58 cM	Ctla4	cytotoxic T-lymphocyte-associated protein 4
Rat	2	223	9q31	Ctla4	cytotoxic T-lymphocyte-associated protein 4

RefSeq Protein

NP_005205 (Hs) , NP_033973 (Mm) , NP_113862 (Rn)

RefSeq Nucleotide

NM_005214 (Hs) , NM_009843 (Mm) , NM_031674 (Rn)

Entrez Gene

1493 (Hs) , 12477 (Mm) , 63835 (Rn)

UniProtKB

P09793 (Mm) , P16410 (Hs)

Ensembl Gene

ENSG00000163599 (Hs) , ENSMUSG00000026011 (Mm) , ENSRNOG00000054129 (Rn)

OMIM

123890 (Hs)

Protein GI

21361212 (Hs) , 31981847 (Mm) , 13928934 (Rn)

DrugBank Target

P16410 (Hs)

CATH/Gene3D

2.60.40.10 (N/A)

ChEMBL Target

CHEMBL2364164 (Hs)

关联配体

Ligand ID	6888
名称	ipilimumab
别名	MDX-010
类别	Antibody
学名	4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide
生物活性评价	The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in ).
评价	Ipilimumab is an anti-CTLA-4 monoclonal antibody. It is likely the subject of patent WO2001014424 , as antibody 10D1 which was investigated further, claimed in patent EP1503794 . Ipilimumab is an immune checkpoint inhibitor.
配体家族	Immune checkpoint modulators
单字母多肽序列
三字母多肽序列
翻译后修饰
化学修饰
临床描述	The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free survival and overall survival compared to Ipilimumab alone. The primary purpose of this study is to compare the objective response rate, as determined by investigators, of Nivolumab combined with Ipilimumab versus Ipilimumab monotherapy in patients with untreated, unresectable, or metastatic melanoma The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.
来源公司	Bristol-Myers Squibb Bristol-Myers Squibb Bristol-Myers Squibb

参考文献

1. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS et al.. (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.. N Engl J Med, 372 (21): (2006-17). [PMID:25891304]
2. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al.. (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.. N Engl J Med, 373 (1): (23-34). [PMID:26027431]
3. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S et al.. (2018) Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.. N Engl J Med, 378 (14): (1277-1290). [PMID:29562145]